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ABSTRACT
CONTEXT AND OBJECTIVE: Nonalcoholic fatty liver disease (NAFLD) has become a public health concern. 
It encompasses a wide spectrum of histological abnormalities and has close relationships with insulin re-
sistance and type 2 diabetes mellitus (T2DM). This study sought to compare the histological alterations 
observed in morbidly obese individuals with and without T2DM who underwent Roux-en-Y gastric bypass. 
DESIGN AND SETTING: Cross-sectional study in a tertiary-level public hospital.
METHODS: This was a cross-sectional study on 197 individuals who underwent gastric bypass surgery 
between 2011 and 2013. NAFLD was assessed through liver biopsies. T2DM was diagnosed through the 
International Diabetes Federation criteria. 
RESULTS: Non-diabetics presented significantly more biopsies without any histological abnormalities, 
regarding steatosis (42.6% versus 25.5%; P = 0.0400), fibrosis (60.6% versus 36.2%; P = 0.0042) and ste-
atohepatitis (27.3% versus 12.8%; P  =  0.0495), while diabetics presented significantly higher frequency 
of moderate forms of steatosis (36.2% versus 20%; P = 0.0307) and fibrosis (23.4% versus 4%; P = 0.0002).
DISCUSSION: T2DM was associated with more advanced forms of NAFLD within the population studied. 
NAFLD has previously been correlated with severe forms of heart disease. 
CONCLUSION: Screening for and early detecting of NAFLD in high-risk populations are important for 
avoiding further development of severe forms and the need for liver transplantation. 
RESUMO
CONTEXTO E OBJETIVO: A doença gordurosa não alcoólica do fígado se tornou um problema de saúde 
pública. Ela compreende um amplo espectro de alterações histológicas e se relaciona intimamente com a 
resistência insulínica e o diabetes mellitus tipo 2. Este estudo tem por objetivo comparar as alterações histo-
lógicas observadas em obesos mórbidos com e sem diabetes submetidos ao bypass gástrico em Y de Roux.
TIPO DE ESTUDO E LOCAL: Estudo transversal em um hospital terciário público.
MÉTODOS: Este é um estudo transversal que envolveu 197 indivíduos submetidos ao bypass gástrico en-
tre 2011 e 2013. A doença gordurosa do fígado foi avaliada através de biópsia hepática. O diabetes mellitus 
tipo 2 foi diagnosticado através dos critérios da Federação Internacional de Diabetes.
RESULTADOS: Indivíduos não diabéticos apresentaram significativamente mais biópsias sem anormali-
dades histológicas, em relação a esteatose (42,6% versus 25,5%; P  =  0.04), fibrose (60,6% versus 36,2%; 
P = 0.0042) e esteato-hepatite (27,3% versus 12,8%; P = 0.0495); os diabéticos apresentaram uma frequên-
cia significativamente mais alta de formas moderadas de esteatose (36,2% versus 20%; P = 0.0307) e fibrose 
(23,4% versus 4%; P = 0.0002).
DISCUSSÃO: O DM-2 associou-se a formas mais avançadas de doença gordurosa do fígado dentro da 
população estudada. A doença gordurosa não alcoólica do fígado foi associada previamente com formas 
graves de doença cardíaca. 
CONCLUSÃO: A busca e detecção precoce da doença gordurosa em populações de alto risco são impor-
tantes para evitar o futuro desenvolvimento de formas graves e a necessidade de transplante hepático.
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INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) has been increasingly diag-
nosed worldwide and is now recognized as a source of public health 
concern. It encompasses a wide spectrum of histological features 
that range from simple steatosis to severe forms of fibrosis, steato-
hepatitis and even cirrhosis.1-3 Its pathogenesis is not completely 
understood, but several abnormalities have been strongly linked to 
its onset, such as central obesity, insulin resistance, chronic inflam-
mation, increased uptake of fatty acids by the liver and lipotoxicity.4,5
NAFLD has been considered to be a hepatic manifestation 
of metabolic syndrome (MetS) and, as such, is strongly related to 
type 2 diabetes mellitus (T2DM). Some studies have correlated 
the severity of insulin resistance with the development of severe 
forms of NAFLD. Moreover, NAFLD has been described as a reli-
able predictor of development of T2DM.6-10
Bariatric surgery has become the standard treatment for mor-
bid obesity, and Roux-en-Y gastric bypass (RYGB) is the surgical 
technique most performed worldwide nowadays.11 Among the mor-
bidly obese individuals who undergo surgery, NAFLD presents high 
prevalence, and liver biopsy during surgery is considered man-
datory in order to address the severity of NAFLD. Several studies 
have observed significant improvement in liver histology following 
RYGB, including complete reversal of liver abnormalities.12-18
OBJECTIVE
This study sought to assess the liver histology observed in a group 
of individuals who underwent Roux-en-Y gastric bypass, in 
order to identify possible differences regarding NAFLD, between 
diabetic and non-diabetic individuals.
METHODS
This was a cross-sectional study in which individuals who under-
went open Roux-en-Y gastric bypass (RYGB) surgery at Hospital 
de Clínicas, Universidade Estadual de Campinas (Unicamp), 
between 2011 and 2013, were enrolled. This study was submit-
ted to and was approved by the local Research Ethics Committee. 
RYGB was indicated in accordance with the American National 
Institutes of Health Consensus Statement criteria. Thus, surgery 
was indicated for individuals who had been obese for at least 
five years, with at least two unsuccessful attempts at conservative 
treatment, with a body mass index (BMI) greater than or equal 
to 40 kg/m2, or greater than or equal to 35 kg/m2 if this was asso-
ciated with obesity-related comorbidities.19 The sample size was 
estimated using a single-proportion formula with a 95% confi-
dence interval. The  precision was set at 5% and the sample size 
thus calculated was 169. The inclusion criteria were that the sub-
jects needed to be between 18 and 65 years of age, and to have 
undergone RYGB. The exclusion criteria comprised membership 
of vulnerable groups (mentally ill, institutionalized or aged below 
18 years); recent or previous abuse of alcohol; antecedents of acute 
or chronic viral hepatitis; serological abnormalities relating to the 
hepatitis B or C virus; previous biliary obstruction; and preopera-
tive biochemical examination data not completely available.
Out of the 302 subjects considered, 197 were selected for this 
study. The reasons for exclusion were: incomplete preoperative 
biochemical examinations in the medical records (77  individ-
uals), previous alcohol abuse (19), serological abnormalities 
relating to chronic viral hepatitis (8) and recently treated biliary 
obstruction caused by gallstones (1). The main characteris-
tics regarding demographics and anthropometric parameters 
were assessed. 
The presence of T2DM was assessed in accordance with the 
criteria defined by the International Diabetes Federation (IDF) 
guidelines. Thus, the presence of T2DM was defined by the 
presence of any of the following abnormalities: fasting plasma 
glucose ≥ 126 mg/dl; 75 g oral glucose tolerance test with two-
hour plasma glucose ≥ 200 mg/dl; glycated hemoglobin (HbA1c) 
≥ 6.5%; and random plasma glucose ≥ 200 mg/dl in the presence 
of classical diabetes symptoms.20
NAFLD was assessed through histological examination of 
liver biopsies carried out during the surgical procedure. Liver 
abnormalities were classified into three categories: 
1. steatosis; 
2. fibrosis; and 
3. steatohepatitis. 
Each category was divided according to the degree of severity: 
1. absent; 
2. mild; 
3. moderate; and 
4. severe.
Statistical analysis
The data were examined to ascertain whether the distribution was 
normal, in accordance with the Shapiro-Wilk test. The chi-square 
test and Fisher’s exact test were used to compare proportions. 
The  Mann-Whitney test was used to compare continuous measure-
ments between independent groups. The significance level used was 
5% (P-value < 0.05). The analysis was performed using the Statistical 
Analysis System (SAS) software for Windows, version 9.2.
RESULTS
Out of the 197 patients selected for this study, 155 (78.7%) were 
female and 42 (21.3%) were male. The mean age at the time of 
surgery was 38.4 years (range, 18-64). The main baseline  charac-
teristics of the subjects are summarized in Table 1. 
The diabetes group comprised 47 individuals (23.8%). 
Diabetics presented significantly older age (44.8 years  ±  9 versus 
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36.3 ± 9.1 years; P < 0.0001) and lower body mass index (44.8 ± 9 kg/m2 
versus 36.3 ± 9.1 kg/m2; P = 0.00714). Weight and gender distribu-
tion did not significantly differ between the groups (Table 1).
Non-diabetics presented significantly more biopsies with-
out any abnormalities regarding steatosis (42.6% versus 25.5%; 
P = 0.0400), fibrosis (60.6% versus 36.2%; P = 0.0042) and ste-
atohepatitis (27.3% versus 12.8%; P  =  0.0495), while diabetics 
presented significantly higher frequency of moderate forms of 
steatosis (36.2% versus 20%; P  =  0.0307) and fibrosis (23.4% 
versus 4%; P  =  0.0002). The frequency of the mild forms did 
not differ in relation to any parameter in the groups. There is a 
detailed summary of the histological findings in Table 1.
DISCUSSION
T2DM is currently considered to be intrinsically linked to 
NAFLD. The exact pathophysiological pathways through which 
these conditions are interconnected are not completely under-
stood, but several metabolic abnormalities are present in both 
of them, especially insulin resistance, defective glucose and lipid 
homeostasis and chronic inflammation.6-10
Since liver biopsies during bariatric surgery are considered 
mandatory, since they can be performed safely and provide use-
ful information, significantly large numbers of subjects may be 
analyzed within this context regarding NAFLD.21-23 On the other 
hand, in non-surgical settings, liver biopsies are not risk-free and 
therefore are not widely available. In these situations, noninva-
sive models that use simple laboratory examinations to assess 
NAFLD have been developed and validated, and may be of great 
usefulness for screening purposes. Of these, the NAFLD fibrosis 
score is the most widely known nowadays.24-27
This study showed that T2DM was significantly associated 
with the presence of NAFLD in a morbidly obese population. 
Furthermore, it was also associated with advanced forms of NAFLD, 
especially the presence of nonalcoholic steatohepatitis (NASH). The 
prevalence of NAFLD among obese adults with T2DM has been esti-
mated to be greater than 70%. Alanine aminotransferase levels have 
been noted to be more than twice the normal levels in 20% of chil-
dren with T2DM, and this is attributed to NAFLD in most cases.28-30 
It is important to emphasize that the diabetic population of 
this study was significantly older than the non-diabetic popula-
tion. Thus, these individuals may have been exposed to insulin 
resistance-related metabolic abnormalities for longer periods, 
possibly leading to liver disease of greater severity and to T2DM 
development from a previous MetS background.
The lower BMI of the diabetic population, compared with the 
non-diabetic population was also notable. This may have been 
due to the fact that surgery is indicated for obese individuals who 
are free of comorbidities when BMI is greater than or equal to 
40 kg/m2. However, the limitations of BMI alone as an index for 
obesity need to be borne in mind. Since insulin resistance and its 
main clinical conditions (MetS and T2DM) are more related to 
central/visceral obesity, BMI may not be so reliable for address 
the severity of obesity within this group, in comparison, for 
example, with waist circumference or waist-to-hip ratio.20
Variable Overall (mean ± SD) DM Non-DM P-value
Number of subjects 197 47 (23.8%) 150 (76.2%) NA
Age (years) 38.4 ± 9.8 (range, 18 – 64) 44.8 ± 9 36.3 ± 9.1 < 0.0001
Gender
Male: 42 (21.3%) Male: 12 (25.5%) Male: 30 (20%)
0.4202
Female: 155 (78.7%) Female: 35 (74.5%) Female: 120 (80%)
Weight (kg) 111.1 ± 15.5 (range, 71.8 – 161.4) 107 ± 13.1 112.1 ± 14.5 0.7234
BMI (kg/m2) 40.6 ± 5.6 (range, 35 – 59.7) 38.6 ± 3.7 41.2 ± 5.9 0.00714
Liver histology
St
ea
to
si
s 1) Absent: 76 (38.6%)
St
ea
to
si
s 1) Absent: 12 (25.5%)
St
ea
to
si
s 1) Absent: 64 (42.6%) 0.0400
2) Mild: 73 (37%) 2) Mild: 18 (38.3%) 2) Mild: 55 (36.7%) 0.8637
3) Moderate: 47 (23.9%) 3) Moderate: 17 (36.2%) 3) Moderate: 30 (20%) (23.9%) 0.0307
4) Severe: 1 (0.5%) 4) Severe: 0 4) Severe: 1 (0.7%) 1.0
Fi
br
os
is
1) Absent: 108 (54.8%)
Fi
br
os
is
1) Absent: 17 (36.2%)
Fi
br
os
is
1) Absent: 91 (60.6%) 0.0042
2) Mild: 70 (35.6%) 2) Mild: 18 (38.3%) 2) Mild: 52 (34.7%) 0.7274
3) Moderate: 17 (8.6%) 3) Moderate: 11 (23.4%) 3) Moderate: 6 (4%) 0.0002
4) Severe: 2 (1%) 4) Severe: 1 (2.1%) 4) Severe: 1 (0.7%) 0.4212
St
ea
to
he
pa
tit
is 1) Absent: 47 (23.9%)
St
ea
to
he
pa
tit
is 1) Absent: 6 (12.8%)
St
ea
to
he
pa
tit
is 1) Absent: 41 (27.3%) 0.0495
2) Mild: 143 (72.6%) 2) Mild: 38 (80.8%) 2) Mild: 105 (70%) 0.1897
3) Moderate: 6 (3%) 3) Moderate: 3 (6.4%) 3) Moderate: 3 (2%) 0.1486
4) Severe: 1 (0.5%) 4) Severe: 0 4) Severe: 1 (0.7%) 1.0
Table 1. Characteristics of subjects and comparison of diabetics versus non-diabetics
DM = diabetes mellitus; SD = standard deviation; BMI = body mass index; NA: not applicable.
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The interconnection between NAFLD and T2DM has been 
noted previously in the literature. Fukuda et al. observed that 
even among non-overweight individuals, NAFLD was an inde-
pendent predictor of T2DM.31 Yamazaki et al. followed up a 
cohort of 4,604 subjects and showed that, in a long-term eval-
uation of individuals with ultrasonographically assessed liver 
disease, that improvement of NAFLD leads to reduced inci-
dence of T2DM.32
NAFLD in diabetic individuals has been linked to severe 
complications of heart disease. Targher et al. demonstrated 
that NAFLD was independently associated with cardiovascu-
lar events, and therefore suggested that NAFLD was not merely 
a marker of cardiovascular disease (CVD) but might also be 
involved in its pathogenesis. The possible molecular mediators 
linking NAFLD and CVD include proatherogenic mediators 
released from the liver, including C-reactive protein, fibrino-
gen and plasminogen activator inhibitor-1.33 Mantovani et al. 
observed that NAFLD is independently associated with early left 
ventricular diastolic dysfunction in type 2 diabetic patients with 
preserved systolic function.34
Since bariatric surgery provides significant weight loss 
and high rates of resolution of metabolic comorbidities, it has 
also been associated with improvement of liver disease. It  is 
now believed that this metabolic improvement is only par-
tially linked to the weight loss itself. In fact, it begins very 
early following surgery, possibly due to structural changes in 
gastrointestinal transit, leading to increased incretin/adipo-
kine activity and immunomodulation. Even individuals with 
severe forms may benefit from surgical outcomes. Considering 
the possible ominous risks of NAFLD/NASH, especially end-
stage liver disease and liver cancer, this benefit is even more 
pronounced.12-18,35-37
This study has some limitations, especially its use of data 
collected from the medical records, which may provide data of 
poor quality and may lead to the impossibility of evaluating a 
considerable number of individuals, because of incomplete med-
ical reports. In this study, incomplete medical records caused 
high loss of subjects who might have been suitable for analysis. 
Furthermore, there were only a few subjects with severe forms of 
NAFLD within the sample studied.
Since NAFLD is nowadays the third most common indica-
tion for liver transplantation in the USA, and it is expected to be 
the first by 2030,38,39 screening and early detection of high-risk 
populations, such as diabetics, may have a major impact on its 
onset and further prognosis.
CONCLUSION
Liver disease occurred more frequently among diabetics in this 
study. T2DM was associated with more advanced forms of NAFLD.
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